Sign In
Buy KROS
$10.50
-0.0500 (-0.474%)
At Close: Jun 03, 2026
Keros Therapeutics, Inc. (KROS) Reports Q3 Loss, Tops Revenue Estimates
06:41pm, Wednesday, 05'th Nov 2025
Keros Therapeutics, Inc. (KROS) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to a loss of $1.41 per share a year ago.
Keros Therapeutics Reports Third Quarter 2025 Financial Results
04:01pm, Wednesday, 05'th Nov 2025
LEXINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and com
Y Intercept Hong Kong Ltd Invests $1.40 Million in Keros Therapeutics, Inc. $KROS
03:41am, Monday, 03'rd Nov 2025
Y Intercept Hong Kong Ltd bought a new position in Keros Therapeutics, Inc. (NASDAQ: KROS) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Ex
Keros Therapeutics (KROS) Moves 9.8% Higher: Will This Strength Last?
10:46am, Tuesday, 21'st Oct 2025
Keros Therapeutics (KROS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price i
Keros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million Shares
06:00am, Monday, 20'th Oct 2025
LEXINGTON, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and com
Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital
06:30am, Wednesday, 15'th Oct 2025
Agrees to Repurchase of All Shares Held By ADAR1 Capital Management and Pontifax Venture Capital Plans to Commence Tender Offer to Repurchase up to $194 Million of Additional Shares LEXINGTON, Mass.,
LEXINGTON, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel t
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
04:01pm, Thursday, 28'th Aug 2025
LEXINGTON, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and com
AUSTIN, Texas , Aug. 21, 2025 /PRNewswire/ -- ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1" or "we"), the largest stockholder of Keros Therapeutics (Nasdaq: KROS) ("Keros" or th
Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy
09:48am, Wednesday, 20'th Aug 2025
LEXINGTON, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel th
Keros Therapeutics, Inc. (KROS) Reports Q2 Loss, Beats Revenue Estimates
06:45pm, Wednesday, 06'th Aug 2025
Keros Therapeutics, Inc. (KROS) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $1.14. This compares to a loss of $1.25 per share a year ago.
Keros to Exclusively Prioritize the Clinical Advancement of KER-065
04:15pm, Wednesday, 06'th Aug 2025
Company Discontinuing Development of Cibotercept (KER-012) Announces Board and Leadership Changes Designed to Support Streamlined Operational Structure and Strategic Realignment LEXINGTON, Mass., Aug.
Keros Therapeutics Reports Second Quarter 2025 Financial Results
04:01pm, Wednesday, 06'th Aug 2025
LEXINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and com
KROS vs. EXAS: Which Stock Should Value Investors Buy Now?
12:41pm, Monday, 28'th Jul 2025
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Keros Therapeutics, Inc. (KROS) and Exact Sciences (EXAS). But which of these two stocks is more att
Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept
08:00am, Thursday, 17'th Jul 2025
LEXINGTON, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel th
